Onychomycosis (Tinea Unguium) Drug  Market Report

Global Onychomycosis (Tinea Unguium) Drug  Market Study Report 2022 Historical Trends, Growth, and Forecast to 2028

  • POSTDATE：Mar 08, 2022
  • PAGES：186
  • REPORT CODE：GMM800321
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Onychomycosis (Tinea Unguium) Drug  market report explains the definition, types, applications, major countries, and major players of the Onychomycosis (Tinea Unguium) Drug  market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.

    The report contains qualitative and quantitative analysis of the entire industry.

    The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.

    By Player:

    • Novartis

    • Valeant Pharma

    • Letai

    • GSK

    • Pfizer

    • Johnson and Johnson

    • Qilu Pharmaceutical

    • Xiuzheng Pharmaceutical

    • Galderma

    • Kaken Pharmaceutical

    By Type:

    • Oral Medication

    • External Medicine

    By End-User:

    • Age under 18

    • Age 18-50

    • Age above 50

    By Region:

    North America

    • United States

    • Canada

    • Mexico

    Europe

    • Germany

    • UK

    • Spain

    • France

    • Italy

    • Denmark

    • Finland

    • Norway

    • Sweden

    • Poland

    • Russia

    • Turkey

    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Pakistan

    • Bangladesh

    • Indonesia

    • Thailand

    • Singapore

    • Malaysia

    • Philippines

    • Vietnam

    • Others

    South America

    • Brazil

    • Colombia

    • Chile

    • Argentina

    • Venezuela

    • Peru

    • Puerto Rico

    • Ecuador

    • Others

    GCC

    • Bahrain

    • Kuwait

    • Oman

    • Qatar

    • Saudi Arabia

    • United Arab Emirates

    Africa

    • Nigeria

    • South Africa

    • Egypt

    • Algeriat

    • Others

    Oceania

    • Australia

    • New Zealand

  • TABLE OF CONTENT

    1. Global Onychomycosis (Tinea Unguium) Drug  Executive Summary

    • 1.1 Introduction

    • 1.2 Market Panorama, 2022

    2 Coronavirus Impact

    • 2.1 Onychomycosis (Tinea Unguium) Drug  Outlook to 2028- Original Forecasts

    • 2.2 Onychomycosis (Tinea Unguium) Drug  Outlook to 2028- COVID-19 Affected Forecasts

    • 2.3 Impact on Industry

    3 Strategic Analytics to Boost Productivity and Profitability

    • 3.1 Potential Market Drivers and Opportunities

    • 3.2 New Challenges and Strategies

    • 3.3 Short Term and Long Term Onychomycosis (Tinea Unguium) Drug  Market Trends

    4 Key Inferences

    5 Market Overview

    • 5.1 Current Market Scenario

    • 5.2 Porter's Five Forces Analysis

      • 5.2.1 Bargaining Power of Suppliers

      • 5.2.2 Bargaining Power of Consumers

      • 5.2.3 Threat of New Entrants

      • 5.2.4 Threat of Substitute Product and Services

      • 5.2.5 Competitive Rivalry within the Industry

    6 Global Onychomycosis (Tinea Unguium) Drug  Market- Recent Developments

    • 6.1 Onychomycosis (Tinea Unguium) Drug  Market News and Developments

    • 6.2 Onychomycosis (Tinea Unguium) Drug  Market Deals Landscape

    7 Onychomycosis (Tinea Unguium) Drug  Raw Materials and Cost Structure Analysis

    • 7.1 Onychomycosis (Tinea Unguium) Drug  Key Raw Materials

    • 7.2 Onychomycosis (Tinea Unguium) Drug  Price Trend of Key Raw Materials

    • 7.3 Onychomycosis (Tinea Unguium) Drug  Key Suppliers of Raw Materials

    • 7.4 Onychomycosis (Tinea Unguium) Drug  Market Concentration Rate of Raw Materials

    • 7.5 Onychomycosis (Tinea Unguium) Drug  Cost Structure Analysis

      • 7.5.1 Onychomycosis (Tinea Unguium) Drug  Raw Materials Analysis

      • 7.5.2 Onychomycosis (Tinea Unguium) Drug  Labor Cost Analysis

      • 7.5.3 Onychomycosis (Tinea Unguium) Drug  Manufacturing Expenses Analysis

    8 Global Onychomycosis (Tinea Unguium) Drug  Import and Export Analysis (Top 10 Countries)

    • 8.1 Global Onychomycosis (Tinea Unguium) Drug  Import by Region (Top 10 Countries) (2017-2028)

    • 8.2 Global Onychomycosis (Tinea Unguium) Drug  Export by Region (Top 10 Countries) (2017-2028)

    9 Global Onychomycosis (Tinea Unguium) Drug  Market Outlook by Types and Applications to 2022

    • 9.1 Global Onychomycosis (Tinea Unguium) Drug  Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Oral Medication Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global External Medicine Consumption and Growth Rate (2017-2022)

    • 9.2 Global Onychomycosis (Tinea Unguium) Drug  Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Age under 18 Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Age 18-50 Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Age above 50 Consumption and Growth Rate (2017-2022)

    10 Region and Country-wise Onychomycosis (Tinea Unguium) Drug  Market Analysis and Outlook till 2022

    • 10.1 Global Onychomycosis (Tinea Unguium) Drug  Consumption (2017-2022)

    • 10.2 North America Consumption Analysis

      • 10.2.1 United States Onychomycosis (Tinea Unguium) Drug  Consumption (2017-2022)

      • 10.2.2 Canada Onychomycosis (Tinea Unguium) Drug  Consumption (2017-2022)

      • 10.2.3 Mexico Onychomycosis (Tinea Unguium) Drug  Consumption (2017-2022)

    • 10.3 Europe Consumption Analysis

      • 10.3.1 Germany Onychomycosis (Tinea Unguium) Drug  Consumption (2017-2022)

      • 10.3.2 UK Onychomycosis (Tinea Unguium) Drug  Consumption (2017-2022)

      • 10.3.3 Spain Onychomycosis (Tinea Unguium) Drug  Consumption (2017-2022)

      • 10.3.4 Belgium Onychomycosis (Tinea Unguium) Drug  Consumption (2017-2022)

      • 10.3.5 France Onychomycosis (Tinea Unguium) Drug  Consumption (2017-2022)

      • 10.3.6 Italy Onychomycosis (Tinea Unguium) Drug  Consumption (2017-2022)

      • 10.3.7 Denmark Onychomycosis (Tinea Unguium) Drug  Consumption (2017-2022)

      • 10.3.8 Finland Onychomycosis (Tinea Unguium) Drug  Consumption (2017-2022)

      • 10.3.9 Norway Onychomycosis (Tinea Unguium) Drug  Consumption (2017-2022)

      • 10.3.10 Sweden Onychomycosis (Tinea Unguium) Drug  Consumption (2017-2022)

      • 10.3.11 Poland Onychomycosis (Tinea Unguium) Drug  Consumption (2017-2022)

      • 10.3.12 Russia Onychomycosis (Tinea Unguium) Drug  Consumption (2017-2022)

      • 10.3.13 Turkey Onychomycosis (Tinea Unguium) Drug  Consumption (2017-2022)

    • 10.4 APAC Consumption Analysis

      • 10.4.1 China Onychomycosis (Tinea Unguium) Drug  Consumption (2017-2022)

      • 10.4.2 Japan Onychomycosis (Tinea Unguium) Drug  Consumption (2017-2022)

      • 10.4.3 India Onychomycosis (Tinea Unguium) Drug  Consumption (2017-2022)

      • 10.4.4 South Korea Onychomycosis (Tinea Unguium) Drug  Consumption (2017-2022)

      • 10.4.5 Pakistan Onychomycosis (Tinea Unguium) Drug  Consumption (2017-2022)

      • 10.4.6 Bangladesh Onychomycosis (Tinea Unguium) Drug  Consumption (2017-2022)

      • 10.4.7 Indonesia Onychomycosis (Tinea Unguium) Drug  Consumption (2017-2022)

      • 10.4.8 Thailand Onychomycosis (Tinea Unguium) Drug  Consumption (2017-2022)

      • 10.4.9 Singapore Onychomycosis (Tinea Unguium) Drug  Consumption (2017-2022)

      • 10.4.10 Malaysia Onychomycosis (Tinea Unguium) Drug  Consumption (2017-2022)

      • 10.4.11 Philippines Onychomycosis (Tinea Unguium) Drug  Consumption (2017-2022)

      • 10.4.12 Vietnam Onychomycosis (Tinea Unguium) Drug  Consumption (2017-2022)

    • 10.5 South America Consumption Analysis

      • 10.5.1 Brazil Onychomycosis (Tinea Unguium) Drug  Consumption (2017-2022)

      • 10.5.2 Colombia Onychomycosis (Tinea Unguium) Drug  Consumption (2017-2022)

      • 10.5.3 Chile Onychomycosis (Tinea Unguium) Drug  Consumption (2017-2022)

      • 10.5.4 Argentina Onychomycosis (Tinea Unguium) Drug  Consumption (2017-2022)

      • 10.5.5 Venezuela Onychomycosis (Tinea Unguium) Drug  Consumption (2017-2022)

      • 10.5.6 Peru Onychomycosis (Tinea Unguium) Drug  Consumption (2017-2022)

      • 10.5.7 Puerto Rico Onychomycosis (Tinea Unguium) Drug  Consumption (2017-2022)

      • 10.5.8 Ecuador Onychomycosis (Tinea Unguium) Drug  Consumption (2017-2022)

    • 10.6 GCC Consumption Analysis

      • 10.6.1 Bahrain Onychomycosis (Tinea Unguium) Drug  Consumption (2017-2022)

      • 10.6.2 Kuwait Onychomycosis (Tinea Unguium) Drug  Consumption (2017-2022)

      • 10.6.3 Oman Onychomycosis (Tinea Unguium) Drug  Consumption (2017-2022)

      • 10.6.4 Qatar Onychomycosis (Tinea Unguium) Drug  Consumption (2017-2022)

      • 10.6.5 Saudi Arabia Onychomycosis (Tinea Unguium) Drug  Consumption (2017-2022)

      • 10.6.6 United Arab Emirates Onychomycosis (Tinea Unguium) Drug  Consumption (2017-2022)

    • 10.7 Africa Consumption Analysis

      • 10.7.1 Nigeria Onychomycosis (Tinea Unguium) Drug  Consumption (2017-2022)

      • 10.7.2 South Africa Onychomycosis (Tinea Unguium) Drug  Consumption (2017-2022)

      • 10.7.3 Egypt Onychomycosis (Tinea Unguium) Drug  Consumption (2017-2022)

      • 10.7.4 Algeria Onychomycosis (Tinea Unguium) Drug  Consumption (2017-2022)

    • 10.8 Oceania Consumption Analysis

      • 10.8.1 Australia Onychomycosis (Tinea Unguium) Drug  Consumption (2017-2022)

      • 10.8.2 New Zealand Onychomycosis (Tinea Unguium) Drug  Consumption (2017-2022)

    11 Global Onychomycosis (Tinea Unguium) Drug  Competitive Analysis

    • 11.1 Novartis

      • 11.1.1 Novartis Company Details

      • 11.1.2 Novartis Onychomycosis (Tinea Unguium) Drug  Sales, Price, Value and Gross Profit (2017-2022)

      • 11.1.3 Novartis Onychomycosis (Tinea Unguium) Drug  Main Business and Markets Served

      • 11.1.4 Novartis Onychomycosis (Tinea Unguium) Drug  Product Portfolio

      • 11.1.5 Recent Research and Development Strategies

    • 11.2 Valeant Pharma

      • 11.2.1 Valeant Pharma Company Details

      • 11.2.2 Valeant Pharma Onychomycosis (Tinea Unguium) Drug  Sales, Price, Value and Gross Profit (2017-2022)

      • 11.2.3 Valeant Pharma Onychomycosis (Tinea Unguium) Drug  Main Business and Markets Served

      • 11.2.4 Valeant Pharma Onychomycosis (Tinea Unguium) Drug  Product Portfolio

      • 11.2.5 Recent Research and Development Strategies

    • 11.3 Letai

      • 11.3.1 Letai Company Details

      • 11.3.2 Letai Onychomycosis (Tinea Unguium) Drug  Sales, Price, Value and Gross Profit (2017-2022)

      • 11.3.3 Letai Onychomycosis (Tinea Unguium) Drug  Main Business and Markets Served

      • 11.3.4 Letai Onychomycosis (Tinea Unguium) Drug  Product Portfolio

      • 11.3.5 Recent Research and Development Strategies

    • 11.4 GSK

      • 11.4.1 GSK Company Details

      • 11.4.2 GSK Onychomycosis (Tinea Unguium) Drug  Sales, Price, Value and Gross Profit (2017-2022)

      • 11.4.3 GSK Onychomycosis (Tinea Unguium) Drug  Main Business and Markets Served

      • 11.4.4 GSK Onychomycosis (Tinea Unguium) Drug  Product Portfolio

      • 11.4.5 Recent Research and Development Strategies

    • 11.5 Pfizer

      • 11.5.1 Pfizer Company Details

      • 11.5.2 Pfizer Onychomycosis (Tinea Unguium) Drug  Sales, Price, Value and Gross Profit (2017-2022)

      • 11.5.3 Pfizer Onychomycosis (Tinea Unguium) Drug  Main Business and Markets Served

      • 11.5.4 Pfizer Onychomycosis (Tinea Unguium) Drug  Product Portfolio

      • 11.5.5 Recent Research and Development Strategies

    • 11.6 Johnson and Johnson

      • 11.6.1 Johnson and Johnson Company Details

      • 11.6.2 Johnson and Johnson Onychomycosis (Tinea Unguium) Drug  Sales, Price, Value and Gross Profit (2017-2022)

      • 11.6.3 Johnson and Johnson Onychomycosis (Tinea Unguium) Drug  Main Business and Markets Served

      • 11.6.4 Johnson and Johnson Onychomycosis (Tinea Unguium) Drug  Product Portfolio

      • 11.6.5 Recent Research and Development Strategies

    • 11.7 Qilu Pharmaceutical

      • 11.7.1 Qilu Pharmaceutical Company Details

      • 11.7.2 Qilu Pharmaceutical Onychomycosis (Tinea Unguium) Drug  Sales, Price, Value and Gross Profit (2017-2022)

      • 11.7.3 Qilu Pharmaceutical Onychomycosis (Tinea Unguium) Drug  Main Business and Markets Served

      • 11.7.4 Qilu Pharmaceutical Onychomycosis (Tinea Unguium) Drug  Product Portfolio

      • 11.7.5 Recent Research and Development Strategies

    • 11.8 Xiuzheng Pharmaceutical

      • 11.8.1 Xiuzheng Pharmaceutical Company Details

      • 11.8.2 Xiuzheng Pharmaceutical Onychomycosis (Tinea Unguium) Drug  Sales, Price, Value and Gross Profit (2017-2022)

      • 11.8.3 Xiuzheng Pharmaceutical Onychomycosis (Tinea Unguium) Drug  Main Business and Markets Served

      • 11.8.4 Xiuzheng Pharmaceutical Onychomycosis (Tinea Unguium) Drug  Product Portfolio

      • 11.8.5 Recent Research and Development Strategies

    • 11.9 Galderma

      • 11.9.1 Galderma Company Details

      • 11.9.2 Galderma Onychomycosis (Tinea Unguium) Drug  Sales, Price, Value and Gross Profit (2017-2022)

      • 11.9.3 Galderma Onychomycosis (Tinea Unguium) Drug  Main Business and Markets Served

      • 11.9.4 Galderma Onychomycosis (Tinea Unguium) Drug  Product Portfolio

      • 11.9.5 Recent Research and Development Strategies

    • 11.10 Kaken Pharmaceutical

      • 11.10.1 Kaken Pharmaceutical Company Details

      • 11.10.2 Kaken Pharmaceutical Onychomycosis (Tinea Unguium) Drug  Sales, Price, Value and Gross Profit (2017-2022)

      • 11.10.3 Kaken Pharmaceutical Onychomycosis (Tinea Unguium) Drug  Main Business and Markets Served

      • 11.10.4 Kaken Pharmaceutical Onychomycosis (Tinea Unguium) Drug  Product Portfolio

      • 11.10.5 Recent Research and Development Strategies

    12 Global Onychomycosis (Tinea Unguium) Drug  Market Outlook by Types and Applications to 2028

    • 12.1 Global Onychomycosis (Tinea Unguium) Drug  Consumption Forecast and Growth Rate by Type (2022-2028)

      • 12.1.1 Global Oral Medication Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.2 Global External Medicine Consumption Forecast and Growth Rate (2022-2028)

    • 12.2 Global Onychomycosis (Tinea Unguium) Drug  Consumption Forecast and Growth Rate by Application (2022-2028)

      • 12.2.1 Global Age under 18 Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.2 Global Age 18-50 Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.3 Global Age above 50 Consumption Forecast and Growth Rate (2022-2028)

    13 Country-wise Onychomycosis (Tinea Unguium) Drug  Market Analysis and Outlook to 2028

    • 13.1 Global Onychomycosis (Tinea Unguium) Drug  Consumption Forecast (2022-2028)

    • 13.2 North America Consumption Analysis

      • 13.2.1 United States Onychomycosis (Tinea Unguium) Drug  Consumption Forecast (2022-2028)

      • 13.2.2 Canada Onychomycosis (Tinea Unguium) Drug  Consumption Forecast (2022-2028)

      • 13.2.3 Mexico Onychomycosis (Tinea Unguium) Drug  Consumption Forecast (2022-2028)

    • 13.3 Europe Consumption Analysis

      • 13.3.1 Germany Onychomycosis (Tinea Unguium) Drug  Consumption Forecast (2022-2028)

      • 13.3.2 UK Onychomycosis (Tinea Unguium) Drug  Consumption Forecast (2022-2028)

      • 13.3.3 Spain Onychomycosis (Tinea Unguium) Drug  Consumption Forecast (2022-2028)

      • 13.3.4 Belgium Onychomycosis (Tinea Unguium) Drug  Consumption Forecast (2022-2028)

      • 13.3.5 France Onychomycosis (Tinea Unguium) Drug  Consumption Forecast (2022-2028)

      • 13.3.6 Italy Onychomycosis (Tinea Unguium) Drug  Consumption Forecast (2022-2028)

      • 13.3.7 Denmark Onychomycosis (Tinea Unguium) Drug  Consumption Forecast (2022-2028)

      • 13.3.8 Finland Onychomycosis (Tinea Unguium) Drug  Consumption Forecast (2022-2028)

      • 13.3.9 Norway Onychomycosis (Tinea Unguium) Drug  Consumption Forecast (2022-2028)

      • 13.3.10 Sweden Onychomycosis (Tinea Unguium) Drug  Consumption Forecast (2022-2028)

      • 13.3.11 Poland Onychomycosis (Tinea Unguium) Drug  Consumption Forecast (2022-2028)

      • 13.3.12 Russia Onychomycosis (Tinea Unguium) Drug  Consumption Forecast (2022-2028)

      • 13.3.13 Turkey Onychomycosis (Tinea Unguium) Drug  Consumption Forecast (2022-2028)

    • 13.4 APAC Consumption Analysis

      • 13.4.1 China Onychomycosis (Tinea Unguium) Drug  Consumption Forecast (2022-2028)

      • 13.4.2 Japan Onychomycosis (Tinea Unguium) Drug  Consumption Forecast (2022-2028)

      • 13.4.3 India Onychomycosis (Tinea Unguium) Drug  Consumption Forecast (2022-2028)

      • 13.4.4 South Korea Onychomycosis (Tinea Unguium) Drug  Consumption Forecast (2022-2028)

      • 13.4.5 Pakistan Onychomycosis (Tinea Unguium) Drug  Consumption Forecast (2022-2028)

      • 13.4.6 Bangladesh Onychomycosis (Tinea Unguium) Drug  Consumption Forecast (2022-2028)

      • 13.4.7 Indonesia Onychomycosis (Tinea Unguium) Drug  Consumption Forecast (2022-2028)

      • 13.4.8 Thailand Onychomycosis (Tinea Unguium) Drug  Consumption Forecast (2022-2028)

      • 13.4.9 Singapore Onychomycosis (Tinea Unguium) Drug  Consumption Forecast (2022-2028)

      • 13.4.10 Malaysia Onychomycosis (Tinea Unguium) Drug  Consumption Forecast (2022-2028)

      • 13.4.11 Philippines Onychomycosis (Tinea Unguium) Drug  Consumption Forecast (2022-2028)

      • 13.4.12 Vietnam Onychomycosis (Tinea Unguium) Drug  Consumption Forecast (2022-2028)

    • 13.5 South America Consumption Analysis

      • 13.5.1 Brazil Onychomycosis (Tinea Unguium) Drug  Consumption Forecast (2022-2028)

      • 13.5.2 Colombia Onychomycosis (Tinea Unguium) Drug  Consumption Forecast (2022-2028)

      • 13.5.3 Chile Onychomycosis (Tinea Unguium) Drug  Consumption Forecast (2022-2028)

      • 13.5.4 Argentina Onychomycosis (Tinea Unguium) Drug  Consumption Forecast (2022-2028)

      • 13.5.5 Venezuela Onychomycosis (Tinea Unguium) Drug  Consumption Forecast (2022-2028)

      • 13.5.6 Peru Onychomycosis (Tinea Unguium) Drug  Consumption Forecast (2022-2028)

      • 13.5.7 Puerto Rico Onychomycosis (Tinea Unguium) Drug  Consumption Forecast (2022-2028)

      • 13.5.8 Ecuador Onychomycosis (Tinea Unguium) Drug  Consumption Forecast (2022-2028)

    • 13.6 GCC Consumption Analysis

      • 13.6.1 Bahrain Onychomycosis (Tinea Unguium) Drug  Consumption Forecast (2022-2028)

      • 13.6.2 Kuwait Onychomycosis (Tinea Unguium) Drug  Consumption Forecast (2022-2028)

      • 13.6.3 Oman Onychomycosis (Tinea Unguium) Drug  Consumption Forecast (2022-2028)

      • 13.6.4 Qatar Onychomycosis (Tinea Unguium) Drug  Consumption Forecast (2022-2028)

      • 13.6.5 Saudi Arabia Onychomycosis (Tinea Unguium) Drug  Consumption Forecast (2022-2028)

      • 13.6.6 United Arab Emirates Onychomycosis (Tinea Unguium) Drug  Consumption Forecast (2022-2028)

    • 13.7 Africa Consumption Analysis

      • 13.7.1 Nigeria Onychomycosis (Tinea Unguium) Drug  Consumption Forecast (2022-2028)

      • 13.7.2 South Africa Onychomycosis (Tinea Unguium) Drug  Consumption Forecast (2022-2028)

      • 13.7.3 Egypt Onychomycosis (Tinea Unguium) Drug  Consumption Forecast (2022-2028)

      • 13.7.4 Algeria Onychomycosis (Tinea Unguium) Drug  Consumption Forecast (2022-2028)

    • 13.8 Oceania Consumption Analysis

      • 13.8.1 Australia Onychomycosis (Tinea Unguium) Drug  Consumption Forecast (2022-2028)

      • 13.8.2 New Zealand Onychomycosis (Tinea Unguium) Drug  Consumption Forecast (2022-2028)

    14 Conclusions


    The List of Tables and Figures

    • Table Definition of Onychomycosis (Tinea Unguium) Drug 

    • Figure of Onychomycosis (Tinea Unguium) Drug  Picture

    • Table Global Onychomycosis (Tinea Unguium) Drug  Import by Region (Top 10 Countries) (2017-2028)

    • Table Global Onychomycosis (Tinea Unguium) Drug  Export by Region (Top 10 Countries) (2017-2028)

    • Figure Global Oral Medication Consumption and Growth Rate (2017-2022)

    • Figure Global External Medicine Consumption and Growth Rate (2017-2022)

    • Figure Global Age under 18 Consumption and Growth Rate (2017-2022)

    • Figure Global Age 18-50 Consumption and Growth Rate (2017-2022)

    • Figure Global Age above 50 Consumption and Growth Rate (2017-2022)

    • Figure Global Onychomycosis (Tinea Unguium) Drug  Consumption by Country (2017-2022)

    • Table North America Onychomycosis (Tinea Unguium) Drug  Consumption by Country (2017-2022)

    • Figure United States Onychomycosis (Tinea Unguium) Drug  Consumption and Growth Rate (2017-2022)

    • Figure Canada Onychomycosis (Tinea Unguium) Drug  Consumption and Growth Rate (2017-2022)

    • Figure Mexico Onychomycosis (Tinea Unguium) Drug  Consumption and Growth Rate (2017-2022)

    • Table Europe Onychomycosis (Tinea Unguium) Drug  Consumption by Country (2017-2022)

    • Figure Germany Onychomycosis (Tinea Unguium) Drug  Consumption and Growth Rate (2017-2022)

    • Figure UK Onychomycosis (Tinea Unguium) Drug  Consumption and Growth Rate (2017-2022)

    • Figure Spain Onychomycosis (Tinea Unguium) Drug  Consumption and Growth Rate (2017-2022)

    • Figure Belgium Onychomycosis (Tinea Unguium) Drug  Consumption and Growth Rate (2017-2022)

    • Figure France Onychomycosis (Tinea Unguium) Drug  Consumption and Growth Rate (2017-2022)

    • Figure Italy Onychomycosis (Tinea Unguium) Drug  Consumption and Growth Rate (2017-2022)

    • Figure Denmark Onychomycosis (Tinea Unguium) Drug  Consumption and Growth Rate (2017-2022)

    • Figure Finland Onychomycosis (Tinea Unguium) Drug  Consumption and Growth Rate (2017-2022)

    • Figure Norway Onychomycosis (Tinea Unguium) Drug  Consumption and Growth Rate (2017-2022)

    • Figure Sweden Onychomycosis (Tinea Unguium) Drug  Consumption and Growth Rate (2017-2022)

    • Figure Poland Onychomycosis (Tinea Unguium) Drug  Consumption and Growth Rate (2017-2022)

    • Figure Russia Onychomycosis (Tinea Unguium) Drug  Consumption and Growth Rate (2017-2022)

    • Figure Turkey Onychomycosis (Tinea Unguium) Drug  Consumption and Growth Rate (2017-2022)

    • Table APAC Onychomycosis (Tinea Unguium) Drug  Consumption by Country (2017-2022)

    • Figure China Onychomycosis (Tinea Unguium) Drug  Consumption and Growth Rate (2017-2022)

    • Figure Japan Onychomycosis (Tinea Unguium) Drug  Consumption and Growth Rate (2017-2022)

    • Figure India Onychomycosis (Tinea Unguium) Drug  Consumption and Growth Rate (2017-2022)

    • Figure South Korea Onychomycosis (Tinea Unguium) Drug  Consumption and Growth Rate (2017-2022)

    • Figure Pakistan Onychomycosis (Tinea Unguium) Drug  Consumption and Growth Rate (2017-2022)

    • Figure Bangladesh Onychomycosis (Tinea Unguium) Drug  Consumption and Growth Rate (2017-2022)

    • Figure Indonesia Onychomycosis (Tinea Unguium) Drug  Consumption and Growth Rate (2017-2022)

    • Figure Thailand Onychomycosis (Tinea Unguium) Drug  Consumption and Growth Rate (2017-2022)

    • Figure Singapore Onychomycosis (Tinea Unguium) Drug  Consumption and Growth Rate (2017-2022)

    • Figure Malaysia Onychomycosis (Tinea Unguium) Drug  Consumption and Growth Rate (2017-2022)

    • Figure Philippines Onychomycosis (Tinea Unguium) Drug  Consumption and Growth Rate (2017-2022)

    • Figure Vietnam Onychomycosis (Tinea Unguium) Drug  Consumption and Growth Rate (2017-2022)

    • Table South America Onychomycosis (Tinea Unguium) Drug  Consumption by Country (2017-2022)

    • Figure Brazil Onychomycosis (Tinea Unguium) Drug  Consumption and Growth Rate (2017-2022)

    • Figure Colombia Onychomycosis (Tinea Unguium) Drug  Consumption and Growth Rate (2017-2022)

    • Figure Chile Onychomycosis (Tinea Unguium) Drug  Consumption and Growth Rate (2017-2022)

    • Figure Argentina Onychomycosis (Tinea Unguium) Drug  Consumption and Growth Rate (2017-2022)

    • Figure Venezuela Onychomycosis (Tinea Unguium) Drug  Consumption and Growth Rate (2017-2022)

    • Figure Peru Onychomycosis (Tinea Unguium) Drug  Consumption and Growth Rate (2017-2022)

    • Figure Puerto Rico Onychomycosis (Tinea Unguium) Drug  Consumption and Growth Rate (2017-2022)

    • Figure Ecuador Onychomycosis (Tinea Unguium) Drug  Consumption and Growth Rate (2017-2022)

    • Table GCC Onychomycosis (Tinea Unguium) Drug  Consumption by Country (2017-2022)

    • Figure Bahrain Onychomycosis (Tinea Unguium) Drug  Consumption and Growth Rate (2017-2022)

    • Figure Kuwait Onychomycosis (Tinea Unguium) Drug  Consumption and Growth Rate (2017-2022)

    • Figure Oman Onychomycosis (Tinea Unguium) Drug  Consumption and Growth Rate (2017-2022)

    • Figure Qatar Onychomycosis (Tinea Unguium) Drug  Consumption and Growth Rate (2017-2022)

    • Figure Saudi Arabia Onychomycosis (Tinea Unguium) Drug  Consumption and Growth Rate (2017-2022)

    • Figure United Arab Emirates Onychomycosis (Tinea Unguium) Drug  Consumption and Growth Rate (2017-2022)

    • Table Africa Onychomycosis (Tinea Unguium) Drug  Consumption by Country (2017-2022)

    • Figure Nigeria Onychomycosis (Tinea Unguium) Drug  Consumption and Growth Rate (2017-2022)

    • Figure South Africa Onychomycosis (Tinea Unguium) Drug  Consumption and Growth Rate (2017-2022)

    • Figure Egypt Onychomycosis (Tinea Unguium) Drug  Consumption and Growth Rate (2017-2022)

    • Figure Algeria Onychomycosis (Tinea Unguium) Drug  Consumption and Growth Rate (2017-2022)

    • Table Oceania Onychomycosis (Tinea Unguium) Drug  Consumption by Country (2017-2022)

    • Figure Australia Onychomycosis (Tinea Unguium) Drug  Consumption and Growth Rate (2017-2022)

    • Figure New Zealand Onychomycosis (Tinea Unguium) Drug  Consumption and Growth Rate (2017-2022)

    • Table Novartis Company Details

    • Table Novartis Onychomycosis (Tinea Unguium) Drug  Sales, Price, Value and Gross Profit (2017-2022)

    • Table Novartis Onychomycosis (Tinea Unguium) Drug  Main Business and Markets Served

    • Table Novartis Onychomycosis (Tinea Unguium) Drug  Product Portfolio

    • Table Valeant Pharma Company Details

    • Table Valeant Pharma Onychomycosis (Tinea Unguium) Drug  Sales, Price, Value and Gross Profit (2017-2022)

    • Table Valeant Pharma Onychomycosis (Tinea Unguium) Drug  Main Business and Markets Served

    • Table Valeant Pharma Onychomycosis (Tinea Unguium) Drug  Product Portfolio

    • Table Letai Company Details

    • Table Letai Onychomycosis (Tinea Unguium) Drug  Sales, Price, Value and Gross Profit (2017-2022)

    • Table Letai Onychomycosis (Tinea Unguium) Drug  Main Business and Markets Served

    • Table Letai Onychomycosis (Tinea Unguium) Drug  Product Portfolio

    • Table GSK Company Details

    • Table GSK Onychomycosis (Tinea Unguium) Drug  Sales, Price, Value and Gross Profit (2017-2022)

    • Table GSK Onychomycosis (Tinea Unguium) Drug  Main Business and Markets Served

    • Table GSK Onychomycosis (Tinea Unguium) Drug  Product Portfolio

    • Table Pfizer Company Details

    • Table Pfizer Onychomycosis (Tinea Unguium) Drug  Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer Onychomycosis (Tinea Unguium) Drug  Main Business and Markets Served

    • Table Pfizer Onychomycosis (Tinea Unguium) Drug  Product Portfolio

    • Table Johnson and Johnson Company Details

    • Table Johnson and Johnson Onychomycosis (Tinea Unguium) Drug  Sales, Price, Value and Gross Profit (2017-2022)

    • Table Johnson and Johnson Onychomycosis (Tinea Unguium) Drug  Main Business and Markets Served

    • Table Johnson and Johnson Onychomycosis (Tinea Unguium) Drug  Product Portfolio

    • Table Qilu Pharmaceutical Company Details

    • Table Qilu Pharmaceutical Onychomycosis (Tinea Unguium) Drug  Sales, Price, Value and Gross Profit (2017-2022)

    • Table Qilu Pharmaceutical Onychomycosis (Tinea Unguium) Drug  Main Business and Markets Served

    • Table Qilu Pharmaceutical Onychomycosis (Tinea Unguium) Drug  Product Portfolio

    • Table Xiuzheng Pharmaceutical Company Details

    • Table Xiuzheng Pharmaceutical Onychomycosis (Tinea Unguium) Drug  Sales, Price, Value and Gross Profit (2017-2022)

    • Table Xiuzheng Pharmaceutical Onychomycosis (Tinea Unguium) Drug  Main Business and Markets Served

    • Table Xiuzheng Pharmaceutical Onychomycosis (Tinea Unguium) Drug  Product Portfolio

    • Table Galderma Company Details

    • Table Galderma Onychomycosis (Tinea Unguium) Drug  Sales, Price, Value and Gross Profit (2017-2022)

    • Table Galderma Onychomycosis (Tinea Unguium) Drug  Main Business and Markets Served

    • Table Galderma Onychomycosis (Tinea Unguium) Drug  Product Portfolio

    • Table Kaken Pharmaceutical Company Details

    • Table Kaken Pharmaceutical Onychomycosis (Tinea Unguium) Drug  Sales, Price, Value and Gross Profit (2017-2022)

    • Table Kaken Pharmaceutical Onychomycosis (Tinea Unguium) Drug  Main Business and Markets Served

    • Table Kaken Pharmaceutical Onychomycosis (Tinea Unguium) Drug  Product Portfolio

    • Figure Global Oral Medication Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global External Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Age under 18 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Age 18-50 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Age above 50 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Onychomycosis (Tinea Unguium) Drug  Consumption Forecast by Country (2022-2028)

    • Table North America Onychomycosis (Tinea Unguium) Drug  Consumption Forecast by Country (2022-2028)

    • Figure United States Onychomycosis (Tinea Unguium) Drug  Consumption Forecast and Growth Rate (2022-2028)

    • Figure Canada Onychomycosis (Tinea Unguium) Drug  Consumption Forecast and Growth Rate (2022-2028)

    • Figure Mexico Onychomycosis (Tinea Unguium) Drug  Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Onychomycosis (Tinea Unguium) Drug  Consumption Forecast by Country (2022-2028)

    • Figure Germany Onychomycosis (Tinea Unguium) Drug  Consumption Forecast and Growth Rate (2022-2028)

    • Figure UK Onychomycosis (Tinea Unguium) Drug  Consumption Forecast and Growth Rate (2022-2028)

    • Figure Spain Onychomycosis (Tinea Unguium) Drug  Consumption Forecast and Growth Rate (2022-2028)

    • Figure Belgium Onychomycosis (Tinea Unguium) Drug  Consumption Forecast and Growth Rate (2022-2028)

    • Figure France Onychomycosis (Tinea Unguium) Drug  Consumption Forecast and Growth Rate (2022-2028)

    • Figure Italy Onychomycosis (Tinea Unguium) Drug  Consumption Forecast and Growth Rate (2022-2028)

    • Figure Denmark Onychomycosis (Tinea Unguium) Drug  Consumption Forecast and Growth Rate (2022-2028)

    • Figure Finland Onychomycosis (Tinea Unguium) Drug  Consumption Forecast and Growth Rate (2022-2028)

    • Figure Norway Onychomycosis (Tinea Unguium) Drug  Consumption Forecast and Growth Rate (2022-2028)

    • Figure Sweden Onychomycosis (Tinea Unguium) Drug  Consumption Forecast and Growth Rate (2022-2028)

    • Figure Poland Onychomycosis (Tinea Unguium) Drug  Consumption Forecast and Growth Rate (2022-2028)

    • Figure Russia Onychomycosis (Tinea Unguium) Drug  Consumption Forecast and Growth Rate (2022-2028)

    • Figure Turkey Onychomycosis (Tinea Unguium) Drug  Consumption Forecast and Growth Rate (2022-2028)

    • Table APAC Onychomycosis (Tinea Unguium) Drug  Consumption Forecast by Country (2022-2028)

    • Figure China Onychomycosis (Tinea Unguium) Drug  Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Onychomycosis (Tinea Unguium) Drug  Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Onychomycosis (Tinea Unguium) Drug  Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Onychomycosis (Tinea Unguium) Drug  Consumption Forecast and Growth Rate (2022-2028)

    • Figure Pakistan Onychomycosis (Tinea Unguium) Drug  Consumption Forecast and Growth Rate (2022-2028)

    • Figure Bangladesh Onychomycosis (Tinea Unguium) Drug  Consumption Forecast and Growth Rate (2022-2028)

    • Figure Indonesia Onychomycosis (Tinea Unguium) Drug  Consumption Forecast and Growth Rate (2022-2028)

    • Figure Thailand Onychomycosis (Tinea Unguium) Drug  Consumption Forecast and Growth Rate (2022-2028)

    • Figure Singapore Onychomycosis (Tinea Unguium) Drug  Consumption Forecast and Growth Rate (2022-2028)

    • Figure Malaysia Onychomycosis (Tinea Unguium) Drug  Consumption Forecast and Growth Rate (2022-2028)

    • Figure Philippines Onychomycosis (Tinea Unguium) Drug  Consumption Forecast and Growth Rate (2022-2028)

    • Figure Vietnam Onychomycosis (Tinea Unguium) Drug  Consumption Forecast and Growth Rate (2022-2028)

    • Table South America Onychomycosis (Tinea Unguium) Drug  Consumption Forecast by Country (2022-2028)

    • Figure Brazil Onychomycosis (Tinea Unguium) Drug  Consumption Forecast and Growth Rate (2022-2028)

    • Figure Colombia Onychomycosis (Tinea Unguium) Drug  Consumption Forecast and Growth Rate (2022-2028)

    • Figure Chile Onychomycosis (Tinea Unguium) Drug  Consumption Forecast and Growth Rate (2022-2028)

    • Figure Argentina Onychomycosis (Tinea Unguium) Drug  Consumption Forecast and Growth Rate (2022-2028)

    • Figure Venezuela Onychomycosis (Tinea Unguium) Drug  Consumption Forecast and Growth Rate (2022-2028)

    • Figure Peru Onychomycosis (Tinea Unguium) Drug  Consumption Forecast and Growth Rate (2022-2028)

    • Figure Puerto Rico Onychomycosis (Tinea Unguium) Drug  Consumption Forecast and Growth Rate (2022-2028)

    • Figure Ecuador Onychomycosis (Tinea Unguium) Drug  Consumption Forecast and Growth Rate (2022-2028)

    • Table GCC Onychomycosis (Tinea Unguium) Drug  Consumption Forecast by Country (2022-2028)

    • Figure Bahrain Onychomycosis (Tinea Unguium) Drug  Consumption Forecast and Growth Rate (2022-2028)

    • Figure Kuwait Onychomycosis (Tinea Unguium) Drug  Consumption Forecast and Growth Rate (2022-2028)

    • Figure Oman Onychomycosis (Tinea Unguium) Drug  Consumption Forecast and Growth Rate (2022-2028)

    • Figure Qatar Onychomycosis (Tinea Unguium) Drug  Consumption Forecast and Growth Rate (2022-2028)

    • Figure Saudi Arabia Onychomycosis (Tinea Unguium) Drug  Consumption Forecast and Growth Rate (2022-2028)

    • Figure United Arab Emirates Onychomycosis (Tinea Unguium) Drug  Consumption Forecast and Growth Rate (2022-2028)

    • Table Africa Onychomycosis (Tinea Unguium) Drug  Consumption Forecast by Country (2022-2028)

    • Figure Nigeria Onychomycosis (Tinea Unguium) Drug  Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Africa Onychomycosis (Tinea Unguium) Drug  Consumption Forecast and Growth Rate (2022-2028)

    • Figure Egypt Onychomycosis (Tinea Unguium) Drug  Consumption Forecast and Growth Rate (2022-2028)

    • Figure Algeria Onychomycosis (Tinea Unguium) Drug  Consumption Forecast and Growth Rate (2022-2028)

    • Table Oceania Onychomycosis (Tinea Unguium) Drug  Consumption Forecast by Country (2022-2028)

    • Figure Australia Onychomycosis (Tinea Unguium) Drug  Consumption Forecast and Growth Rate (2022-2028)

    • Figure New Zealand Onychomycosis (Tinea Unguium) Drug  Consumption Forecast and Growth Rate (2022-2028)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US